{"id":"W2385064459","doi":"10.1093/cid/ciw207","title":"Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study","year":2016,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Hip and Knee Clinic; AIDS Vancouver","funders":"Cilag; Canadian Institutes of Health Research; University of New South Wales; Mylan; GlaxoSmithKline; ViiV Healthcare; Australian Government; Gilead Sciences; Quest Diagnostics; Pfizer; Bristol-Myers Squibb","keywords":"Maraviroc; Virology; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Medicine; Ritonavir; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Viral replication; CCR5 receptor antagonist; Human immunodeficiency virus (HIV); Virus; Viral disease; Biology; Viral load; Polymerase chain reaction; Sida; Immunology; Antiretroviral therapy; Genetics; Gene; Chemokine receptor; Chemokine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002147756,0.001161289,0.001766958,0.0003457435,0.0002933877,0.001031361,0.0007570209,0.001135178,0.003032311],"category_scores_gemma":[0.001753944,0.0004853628,0.00189884,0.0002852611,0.0007685676,0.001008816,0.0004040273,0.002247225,0.0003820059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000663655,"about_ca_system_score_gemma":0.0007253914,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007675487,"about_ca_topic_score_gemma":0.001377459,"domain_scores_codex":[0.9992257,0.0004073344,0.00005169262,0.0001231171,0.00007508059,0.0001171013],"domain_scores_gemma":[0.9989004,0.0002930029,0.0002716196,0.0000958647,0.00005868402,0.0003803588],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9700355,0.006991048,0.00262877,0.0001811081,0.0007548115,0.00004281599,0.00005664979,0.0003220406,0.003744971,0.00005633538,0.0003957738,0.01479026],"study_design_scores_gemma":[0.7596979,0.2273822,0.009257021,0.00003448842,0.0009356471,0.00008230224,0.00004872774,0.0007286611,0.001059715,0.0001476452,0.0006031364,0.00002269669],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977443,0.001088541,0.00009825575,0.0001362561,0.00007351686,0.0002761167,0.0002119363,0.00001763471,0.0003534705],"genre_scores_gemma":[0.9971417,0.0007519128,0.0003724516,0.0003302068,0.0001731012,0.0003512243,0.000384442,0.000008175674,0.0004869329],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003032311,"threshold_uncertainty_score":0.0113585,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01726898110364967,"score_gpt":0.2867365728982774,"score_spread":0.2694675917946277,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}